that mild, persistent hyperketonemia, such as those caused by If SGLT2i and GLP-1 RA are administered together there SGLT2i, mainly β-hydroxybutyrate, is freely taken up by the heart might be a greater benefit in the rates of death, CVD death, and and is oxidized in priority to ...
the cellular mechanisms associated with CV protection afforded by these agents, investigating a pleiotropic range of potential effects to improve bone marrow (BM), kidney, heart, and vascular health. Additionally, there is gr...
持续葡萄糖监测(CGM)能提供连续、全面、可靠的血糖情况,发现不易被传统监测方法所探测到的隐匿性高血糖和低血糖,同时提供 TIR 等信息,过去常用于胰岛素治疗的 1 型或 2 型糖尿病(T1DM/T2DM)患者的血糖监测[4]。而胰高糖素样肽-1...
持续葡萄糖监测(CGM)能提供连续、全面、可靠的血糖情况,发现不易被传统监测方法所探测到的隐匿性高血糖和低血糖,同时提供 TIR 等信息,过去常用于胰岛素治疗的 1 型或 2 型糖尿病(T1DM/T2DM)患者的血糖监测[4]。而胰高糖素样肽-1 受体激动剂(GLP-1RA)和钠-葡萄糖共转运蛋白 2 抑制剂(SGLT2i)等控糖新药,...
hospital or suffering potential fatal consequences. This trial is investigating if a tablet called sotagliflozin, can improve quality of life in people with type 1 diabetes and heart failure. In addition, this trial will also assess the safety and tolerability of sotagliflozin in this population....
SGLT-2i plus GLP-1RA therapy was generally well tolerated, with a low risk of hypoglycemia and no unexpected findings. Taken together with results from large CV outcomes trials of SGLT-2is and GLP-1RAs, combination therapy with these agents potentially provides effective durable glycemic control ...
and GLP-1 RA therapy initiation in eligible patients with cardiorenal risk; importantly, we note that this clinical inertia is contrary to a wealth of evidence from CVOTs, and despite updates to clinical guidelines that encourage SGLT2i and GLP-1 RA use. We also find that low uptake of ...
and GLP-1 RA therapy initiation in eligible patients with cardiorenal risk; importantly, we note that this clinical inertia is contrary to a wealth of evidence from CVOTs, and despite updates to clinical guidelines that encourage SGLT2i and GLP-1 RA use. We also find that low uptake of ...
DPP-4抑制剂通过选择性抑制DPP-4,可以升高内源性GLP-1和GIP的水平,从而调节血糖。 现有的对糖尿病发病机制的认识包括以下八个方面:胰岛素分泌受损、胰高糖素分泌增多、肝糖生成增多、肠促胰素反应降低、神经递质功能障碍、肌肉组织葡萄糖摄取减少、脂解作用增强,肾脏葡萄糖重吸收增加。其中独缺肾脏靶点的治疗手段。
SGLT2i’s are unique in their overall catabolic profile: (1) Blood glucose is lowered mainly by direct urinary excretion and NOT via an increase in insulin levels. (2) As a consequence of the lowered blood glucose levels, plasma insulin levels drop. (3) SGLT2 inhibition produces a net ...